About
About
Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.

About Us
Immunic Therapeutics
Immunic is developing a clinical pipeline of orally administered, small molecule therapies:
The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026. Initiation of an additional phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1, or Nurr1, activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase, or DHODH.
The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases.
The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026. Initiation of an additional phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1, or Nurr1, activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase, or DHODH.
The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases.
Immunic, Inc. is headquartered in New York City…
Immunic, Inc. is headquartered in New York City. Its subsidiary, Immunic AG, is based in Gräfelfing near Munich, Germany, where the company’s research and development activities are conducted.
Immunic AG was founded in 2016 with...
Immunic AG was founded in 2016 with headquarters in Planegg-Martinsried, Germany. Since April 2019, the company has been operating under the name Immunic, Inc. with its registered office in the United States and has been trading on the Nasdaq Stock Market under the ticker symbol ”IMUX.”
Management
Questions?
Get in touch.
Immunic, Inc. (Nasdaq: IMUX) Stock Quote:
Currency in USD. Quote data delayed at least 15 minutes.

















